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Abstract
Background: Prostate cancer is the second most frequently diagnosed cancer in men. Animal
models that closely mimic clinical disease in humans are invaluable tools in the fight against prostate
cancer. Recently, a Simian Virus-40 T-antigen (SV-40 Tag) targeted probasin promoter rat model
was developed. This model, however, has not been extensively characterized; hence we have
investigated the ontogeny of prostate cancer and determined the role of sex steroid receptor and
insulin-like growth factor-1 (IGF-1) signaling proteins in the novel SV-40 Tag rat.
Methods:  The SV-40 Tag rat was histopathologically characterized for time to tumor
development, incidence and multiplicity and in the ventral, dorsal, lateral and anterior lobes of the
prostate. Immunoassay techniques were employed to measure cell proliferation, apoptosis, and sex
steroid receptor and growth factor signaling-related proteins. Steroid hormone concentrations
were measured via coated well enzyme linked immunosorbent assay (ELISA) kits.
Results: Prostatic intraepithelial neoplasia (PIN) and well-differentiated prostate cancer developed
as early as 2 and 10 weeks of age, respectively in the ventral prostate (VP) followed by in the
dorsolateral (DLP). At 8 weeks of age, testosterone and dihydrotestosterone (DHT)
concentrations in SV-40 Tag rats were increased when compared to non-transgenic rats. High cell
proliferation and apoptotic indices were found in VP and DLP of transgenic rats. Furthermore, we
observed increased protein expression of androgen receptor, IGF-1, IGF-1 receptor, and
extracellular signal-regulated kinases in the prostates of SV-40 Tag rats.
Conclusion: The rapid development of PIN and prostate cancer in conjunction with the large
prostate size makes the SV-40 Tag rat a useful model for studying prostate cancer. This study
provides evidence of the role of sex steroid and growth factor proteins in prostate cancer
development and defines appropriate windows of opportunity for preclinical trials and aids in the
rational design of chemoprevention, intervention, regression, and therapeutic studies using
prostate cancer rodent models.
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Background
Prostate cancer is the second most frequently diagnosed
cancer in men, with 782,600 new cases projected to occur
in 2007 [1]. It was estimated that 254,000 deaths would
occur from prostate cancer in the past year. One of the first
means of prostate cancer treatment was androgen depriva-
tion and estrogen administration [2]. Hence, it is known
that sex steroids and their receptors play a major role in
prostate cancer etiology. The androgen receptor (AR) is
believed to participate in prostate cancer progression,
including its activation and up-regulation, point muta-
tions, and ligand-independent activation. Testosterone, a
ligand for the AR, is secreted primarily by the testes and is
subsequently converted to DHT via  the enzyme, 5-α-
reductase. DHT has a 50-fold higher binding affinity for
AR and is 10 times more potent than testosterone [3].
Whether or not elevated blood levels of androgens are a
significant risk factor for prostate cancer is open for
debate. Some have reported that increased testosterone
levels in the blood are associated with an increased risk of
prostate cancer [4]. Others have failed to support the
"androgen hypothesis" that circulating testosterone and
DHT are positively associated with prostate cancer risk [5].
Estrogens and their receptors, including estrogen receptor-
alpha (ER-alpha) and estrogen receptor-beta (ER-beta),
play an integral role in normal growth, differentiation,
and development of the prostate. In a study of over 600
men, low circulating concentrations of estradiol were
associated with a decreased risk of prostate cancer [4]. In
the past, estrogens have been used to treat prostate cancer
because it resulted in prostate growth inhibitory effects.
However, toxicity and poor response rate associated with
estrogen therapy have hindered its progress in treating
prostate cancer. The timing of administration and dose
often dictates the type of response produced by estrogens
or estrogen-like chemicals [6].
Growth factor signaling also plays a critical role in the
growth and development of the prostate, including the
proteins of the insulin-like growth factor axis. The two
growth factors, IGF-1 and IGF-2, interact with 6 known
IGF-binding proteins (IGF-BPs), which regulate binding
to the 2 IGF receptors (IGF-1R and IGF-2R). Elevated lev-
els of IGF-1 and decreased levels of IGF-BP3 in the blood
serum have been associated with an increased risk of
advanced stage prostate cancer [7]. Additional support to
the role of IGF-1 and prostate growth can be found in IGF-
1 deficient mice that exhibit decreased prostate size [8]
and increased rat prostate growth with systemic adminis-
tration of IGF-1 [9]. The expression of IGF-1R in prostate
cancer remains controversial. It has been proposed that
reduced IGF-1R action is necessary for prostate cancer pro-
gression. Tennant et al. reported that IGF-1R expression is
abundant in normal and early-stage tumors, but reduced
in advanced and metastatic prostate cancer [10]. The IGF-
1 signal transduction cascade ultimately leads to the phos-
phorylation of intracellular substrates and activation of
the mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) pathway. The MAPK/ERK
pathway is involved in cell differentiation, cell survival,
and cell migration [11]. ERKs, downstream effectors of
growth factor and sex steroid receptor signaling, also reg-
ulate cell proliferation and apoptosis and participate in
prostate carcinogenesis [11]. Furthermore, the MAPK/ERK
signaling has the ability to re-activate the AR pathway by
a hormone-independent mechanism that may lead to
androgen-independent prostate cancer [12].
Animal models that closely mimic clinical disease in
humans are invaluable tools in the fight against prostate
cancer. The TRAMP model developed in 1995 has been
used extensively as a prostate cancer model over the past
decade [13]. One limitation of the TRAMP model, how-
ever, is that it is mouse-based; therefore, the prostates are
very small and necessitate several dissected prostate lobes
to allow extensive mechanism of action research at the
protein level. Recently, Shirai and colleagues developed
another SV-40 Tag targeted probasin promoter rodent
model, this one in the Sprague Dawley rat [14]. However,
this model has not been extensively characterized. Accord-
ingly, we set out to thoroughly characterize the histopa-
thology of autochthonous prostate cancer in the SV-40
Tag rat.
The goal of this study was to define appropriate windows
of opportunity for pre-clinical trails using the SV-40 Tag
rat. We report the incidence and pathological changes
within the VP and DLP as a function of time throughout
the natural history of prostate cancer in SV-40 Tag rats.
Furthermore, we evaluated the role of sex steroid receptor
and IGF-1 signaling proteins, cell proliferation, and apop-
tosis in the development of prostate cancer in this model.
This study should aid in the rational design of chemopre-
vention, intervention, regression, and therapeutic studies
using prostate cancer rodent models.
Methods
Animals
Animal care and use were conducted according to estab-
lished guidelines approved by the National Institutes of
Health and the Institutional Animal Care and Use Com-
mittee at the University of Alabama at Birmingham. Ani-
mals were housed in rooms maintained at 24 ± 1°C with
a 12 hr light-dark cycle. All animals received powdered
phytoestrogen-free AIN-76A diet (Harlan Teklad Global
Diets, Wilmington, DE) and tap water.
SV-40 Tag rat breeders were provided for us by Dr. Tomoy-
uki Shirai of Nagoya City University Medical School viaBMC Cancer 2009, 9:30 http://www.biomedcentral.com/1471-2407/9/30
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Drs. Gail Prins and Steve Swanson of the University of Illi-
nois at Chicago. Heterozygous SV-40 Tag females were
crossed with non-transgenic males to generate hetero-
zygous SV-40 Tag male offspring (SV-40 SD females × SD
male breeders). Day 21 post-conception females were
anesthetized and the offspring were caesarian-derived to
yield mycoplasma-free offspring that were used to estab-
lish our colony. At 3 weeks of age, the offspring were
weaned and tails were clipped. DNA was extracted using a
DNeasy Tissue Kit (Qiagen, Valencia, CA), and a PCR-
based screening assay was performed to evaluate trans-
gene incorporation [13-15].
Rats were necropsied starting at day 1 post-partum, once
per week from 1 to 6 weeks, and every 2 weeks starting at
6 weeks of age and concluding at 40 weeks. At time of dis-
section, prostates were excised, weighed, and flash frozen
in liquid nitrogen. Because it is unclear which lobe in the
rodent resembles the human peripheral zone, the pros-
tatic location in humans where prostate cancer normally
occurs [16], we chose to analyze both the DLP, which has
historically been referred to as the homologue of the
human prostate [17] and the VP. Blood was collected at
sacrifice, centrifuged at 3,000 × g and serum was stored at
-80°C until time of analysis.
Histopathology
At necropsy, organs were examined for gross abnormali-
ties. Macro-metastasis to the bone, abdominal wall,
lymph nodes, liver, kidney, and lung was investigated.
Prostate, testes, seminal vesicles and tumor weights were
also recorded. The prostate and organs of suspected
metastasis were placed in cassettes, immersed in 10% for-
malin, dehydrated in a series of alcohol dilutions, fixed in
xylene, embedded in paraffin wax, sliced into 5 μm sec-
tions, and placed on microscope slides as described by
Folkvord et al. [18]. Sections were stained with hematoxy-
lin and eosin prior to histopathological examination. Dr.
Isam Eltoum, a Board Certified Pathologist, blindly
scored each coded sample using the following grading
scale developed specifically for rodents [16,19-21]: Grade
1 (non-cancerous), Grade 2 (low-grade PIN), Grade 3
(HG-PIN), Grade 4 (well-differentiated lesion), Grade 5
(moderately differentiated lesion), or Grade 6 (poorly dif-
ferentiated lesion).
Sex Steroid Hormone Concentrations in Blood Serum
Serum total testosterone, DHT, and estradiol concentra-
tions were measured in the blood serum using coated-well
enzyme- and radio-immunoassays (Diagnostic Systems
Laboratories, Inc., Webster, TX) as described by the man-
ufacturer. The following kits were used: DSL 10–4000
(total testosterone), DSL 9600 (DHT), and DSL 4800
(estradiol). All samples were run in duplicate with eight
samples per group by Dr. Richard Parker (Obstetrics and
Gynecology Department, UAB, Birmingham, AL). Stand-
ards provided by the manufacturer were used: 0.1–25 ng/
mL for total testosterone, 25–2500 pg/mL for DHT, and
20–6000 pg/mL for estradiol. Sensitivity for total testo-
sterone, DHT, and estradiol were 0.04 ng/mL, 4 pg/mL,
and 7 pg/mL, respectively.
IGF-1 Concentrations in Blood Serum
IGF-1 concentrations were measured in blood serum
using a coated well ELISA kit as described by Diagnostic
Systems Laboratories, Inc. All samples were run in dupli-
cate with eight samples per group. Concentration (ng/mL)
of samples and controls were determined by plotting the
mean absorbance readings of the controls and unknowns
against the mean absorbance readings of all standards in
a four-parameter curve fit.
Cell Proliferation
Prostate tissues (VP and DLP) were harvested and proc-
essed for detecting Ki-67, a marker of cell proliferation as
previously described [21]. Slides were viewed using a
Nikon Labophot-2 microscope (Nikon Corporation,
Tokyo, Japan) and digitally recorded using a Nikon 8.0
Mega Pixels CoolPix 8700 Digital Camera (Nikon). For
Ki67 quantitation, epithelial cells were counted using
Image J software (Image J, NIH). The VP and DLP were
analyzed separately (a minimum of 1,000 cells counted
per lobe per slide. The epithelial cells staining positive
(brown) for Ki67 were counted as well as the non-prolif-
erative epithelial cells (stained blue). The proliferative
index was defined as the number of positively stained epi-
thelial cells divided by the total number of epithelial cells
counted × 100. Twenty-eight week old TRAMP prostate
tumor with and without Ki67 primary antibody was used
as positive and negative controls, respectively.
Apoptosis
The ApopTag® Plus Peroxidase In Situ Apoptosis Detection
Kit (Chemicon International, Temecula, CA) was used to
measure apoptosis following the manufacturer's instruc-
tions. The apoptotic index was defined as the number of
epithelial cells stained positive (brown) for apoptosis
divided by the total number of epithelial cells counted ×
100. Visualization was performed using a Nikon light
microscope, Nikon digital camera, and analyzed using
Image J software (NIH).
Immunoblot Analyses
When possible, protein expression levels of sex steroid
and growth factor receptors and their ligands were meas-
ured by western blot analysis as described previously [22].
Tissues (8 biological samples/treatment group) were
homogenized in lysis buffer (1% Triton X-100, 10 mM
Tris (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1 mM Hepes (pH
7.6), 2 mM Na vanadate, 0.2 mM PMSF, 2 μg/ml leupep-BMC Cancer 2009, 9:30 http://www.biomedcentral.com/1471-2407/9/30
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tin, 2 μg/ml aprotinin). Protein concentration of each
sample was determined using the Pierce BCA Protein
Assay (Pierce, Rockford, IL). The same quantity of protein
from each sample was separated by SDS-PAGE and trans-
ferred to a nitrocellulose membrane (BioRad, Hercules,
CA). The membranes were blocked and immunoblotted
with appropriate antibodies purchased from Cell Signal-
ing Technology (Danvers, MA): total Extracellular Regu-
lating Kinases 1 and 2 (total-ERKs 1 and 2) (#9102) and
Phosphatase and Tensin Homolog (PTEN) (#9554), and
from Santa Cruz Biotechnology (Santa Cruz, CA): AR (SC-
816), ER-alpha (SC-7207), insulin-like growth factor-1
receptor alpha (IGF-1R-α) (SC-712), phospho-Akt 1/2/3
(SC-7985), and β-actin (SC-47778) was used as a loading
control. Positive protein controls purchased from the sup-
pliers of the corresponding antibodies and the use of
Kaleidoscope Precision Plus Protein and Pre-stained SDS-
PAGE Broad Range standards (BioRad Hercules, CA) were
employed to identify the protein of interest. After incuba-
tion with HRP-conjugated secondary antibody (Cell Sign-
aling Technology), bands were detected using
chemiluminescence (Pierce) and exposed to X-ray radiog-
raphy film. Band intensity was quantified using scanning
densitometry.
Enzyme Linked Immunosorbent Assays
IGF-1 protein levels were quantified in the prostate by
ELISA as described by Crowther et al. [23] with modifica-
tions [22]. Prior to analysis, kinetic curves were set up to
establish zero order kinetics. Samples were run in tripli-
cate and the absorbance at 450 nm was read in an OPTI
max Microplate reader (Molecular Devices, Sunnyvale,
CA). Rat liver with and without IGF-1 primary antibody
was used as a positive and negative control, respectively.
Statistics
Statistical comparisons were performed using two-tailed
Students t-test assuming unequal variances for immunob-
lot analysis and ELISA. Trend analysis was implemented
to compare cell proliferation and apoptosis between non-
transgenic and SV-40 Tag rats. P < 0.05 was considered to
be significant. GraphPad™Prism 5.0 and GraphPad™
InStat 3.0 (San Diego, CA) were used to assist in statistical
analysis.
Results
Histopathology
Via the ontogeny study, we found that precursor lesion
and prostate tumor progression was more rapid in the VP
than the DLP of SV-40 Tag rats (Table 1). Prostates were
graded normal (Grade 1) from day 1 through 1 week post-
partum. However, low-grade PIN (Grade 2) quickly devel-
oped as early as 2 weeks of age in the VP and DLP. High-
grade PIN (Grade 3), the precursor to prostate adenocarci-
Table 1: Histopathological analysis of the ventral and 
dorsolateral prostate lobes of SV-40 Tag rats fed control AIN-
76A diet
Histopathological
Grades
Histopathological
Grades
Age n (Ventral Prostate) (Dorsolateral prostate)
1 day 2 1, 1 1, 1
1 week 4 1, 1, 1, 1 1, 1, 1, 1
2 weeks 6 2, 2, 2, 2, 2, 2 1, 1, 2, 2, 2, 2
3 weeks 2 2, 2 2, 2
4 weeks 2 3, 3 2, 2
5 weeks 4 2, 2, 3, 3 1, 2, 2, 3
6 weeks 3 3, 3, 3 3, 3, 3
8 weeks 5 3, 3, 3, 3, 3 3, 3, 3, 3, 3
10 weeks 5 3, 3, 3, 4, 4 3, 3, 3, 3, 3
12 weeks 5 4, 4, 4, 4, 5 3, 3, 3, 3, 3
14 weeks 5 4, 4, 4, 4, 4 4, 4, 4, 4, 4
16 weeks 5 4, 5, 5, 5, 5 3, 3, 4, 4, 4
18 weeks 5 4, 5, 5, 5, 5 3, 4, 4, 4, 4
20 weeks 4 5, 5, 5, 5 4, 4, 4, 4
22 weeks 4 5, 5, 5, 5 5, 5, 5, 5
24 weeks 4 5, 5, 5, 5 5, 5, 5, 5
26 weeks 4 5, 5, 5, 6 3, 5, 6, 6
28 weeks 3 5, 6, 6 5, 5, 6
30 weeks 3 4, 6, 6 4, 6, 6
32 weeks 3 5, 5, 5 5, 5, 5
36 weeks 3 5, 5, 5 5, 5, 5
40 weeks 4 5, 5, 5, 5 5, 5, 5, 5
Tissue sections were evaluated for histopathological scores of 1 (no 
tumor), 2 (low grade PIN), 3 (high-grade PIN), 4 (well-differentiated 
tumor), 5 (moderately differentiated tumor), and 6 (poorly 
differentiated tumor) depending on the presence and progression of 
lesions. Individual grades are presented for each age group and lobe.BMC Cancer 2009, 9:30 http://www.biomedcentral.com/1471-2407/9/30
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noma, developed as early as 4 and 5 to 6 weeks of age in
the VP and DLP, respectively. None of the animals aged 8
weeks or younger developed cancerous lesions (Grade 4
or greater).
The first incidence of prostate cancer (well-differentiated
lesions/Grade 4) developed at 10 and 14 weeks of age in
the VP and DLP, respectively. By 10 weeks of age, 40% of
animals developed prostate cancer in the VP, whereas by
14 weeks of age 100% of animals developed prostate
cancer in the DLP. In addition, 100% of the rats had
prostate cancer in each lobe by 14 weeks of age. Moder-
ately-differentiated lesions (Grade 5) developed as early
as 16 and 22 weeks of age in the VP and DLP, respec-
tively. Poorly-differentiated lesions (Grade 6) developed
at 26–30 weeks of age in the VP and DLP. When one lobe
demonstrated Grade 6 lesions, the other lobe usually
also exhibited Grade 6 lesions. Interestingly, from 32–40
weeks only moderately-differentiated lesions (Grade 5)
and not poorly differentiated lesions (Grade 6) were
found. Only 5% of SV-40 Tag rats developed macro-
scopic prostate tumors in which prostate lobes were
indistinguishable at dissection (3.18 ± 2.16 grams). In
30 week old SV-40 Tag rats which developed Grade 4–6
lesions without macroscopic tumors, the prostate tissue
weighed 1.27 ± 0.19 grams. This is to be compared to age
matched non-transgenic rat prostates weighing 1.04 ±
0.20 grams. Metastasis to the pelvic lymph nodes, ure-
thra, or kidneys was observed in less than 5% of SV-40
Tag rats at 30 weeks of age or older. Macro- or micro-
metastasis was not observed in any animals younger
than 30 weeks of age.
Blood Sex Steroid Concentrations
Circulating androgens were measured in the blood via
immunoassay to investigate their potential role in prostate
cancer etiology. In non-transgenic rats peak total testoster-
one concentrations were found at 12 weeks (Figure 1A).
However, in SV-40 Tag rats, peak testosterone concentrations
were found at 8 weeks at concentrations that were 4 fold of
those in non-transgenic rats a the same age (p < 0.001). This
preceded prostate cancer development in the VP by 2 weeks
in SV-40 Tag rats (Table 1). Total testosterone in the blood
serum of SV-40 Tag rats at 8, 12, 20, and 30 weeks of age were
significantly higher by 11-fold, 10-fold, 6-fold, and 3.3-fold,
respectively, when compared to concentrations at 4 weeks of
age in SV-40 Tag rats (P < 0.05).
In non-transgenic rats, serum DHT concentrations were
highest in the prepubertal period, that is, at 4–6 weeks old
(Figure 1B). Thereafter, DHT concentrations decreased. In
SV-40 Tag rats, serum DHT concentrations were similar at
4–6 weeks, but at 8 weeks, DHT concentrations were
found to be significantly increased 2.3-fold in the SV-40
Tag rats when compared to non-transgenic rats at the
same age (p < 0.001). Then in SV-40 Tag rats, DHT con-
centrations progressively decreased. Increasing DHT con-
centrations at 8 weeks in SV-40 Tag rats accompanied PIN
development between 4 to 8 weeks of age (Figure 1B and
Table 1). Calculating DHT to testosterone ratios revealed
significantly higher values at 4 weeks of age when com-
pared to 8 weeks or older in SV-40 Tag rats and non-trans-
genic rats (data not shown). At all ages investigated,
however, there were no significant differences in DHT to
testosterone ratios between transgenic and non-transgenic
rats.
Androgen concentrations in the blood serum of SV-40 Tag and non-transgenic rats fed AIN-76A diet Figure 1
Androgen concentrations in the blood serum of SV-40 Tag and non-transgenic rats fed AIN-76A diet. A) Testo-
sterone concentrations. B) Dihydrotestosterone concentrations. Each age group had at least 5 animals per group. Values are 
presented as the mean ± SEM. In non-transgenic rats, androgen concentrations were not determined at 24 and 30 weeks.
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Serum estradiol 17-β concentrations in non-transgenic
rats were highest at 6 to 8 weeks, and then gradually
decreased (Figure 2). In the SV-40 Tag rats, serum estra-
diol 17-β concentrations at 4, 6, 8 and 12 weeks were sig-
nificantly lower than those in non-transgenic rats at these
same ages (P  < 0.05). Thereafter, serum estradiol 17-β
from SV-40 Tag rats increased to concentrations similar to
those of non-transgenic rats at 20 to 30 weeks. In non-
transgenic compared to SV-40 Tag rats, estrogen to testo-
sterone ratios were calculated to be 24 and 5.5 fold higher
at 4 and 8 weeks, respectively. At other times that were
investigated, the estrogen to testosterone ratios were not
significantly different. From 4 weeks through 20 weeks,
the estrogen to DHT ratios were 2–4 fold higher in non-
transgenic compared to SV-40 Tag rats.
IGF-1 Concentrations in Blood Serum
IGF-1 concentrations in the blood of non-transgenic and
SV-40 Tag rats were found to be lowest at the youngest age
investigated, 4 weeks postpartum (Figure 3). In non-trans-
genic rats, IGF-1 concentrations increased 2-fold and
peaked at 12 weeks, and then gradually decreased with
age. In the SV-40 Tag rats, serum IGF-1 concentrations sig-
nificantly increased by 3-fold between 4 and 6 weeks of
age (P < 0.05), increased steadily thereafter, and peaked at
20 to 30 weeks of age. Thereafter, serum IGF-1 concentra-
tions significantly decreased by 2.5 fold at 36–40 weeks of
peak concentrations. Only at 4 weeks postpartum were
serum IGF-1 concentrations found to be significantly dif-
ferent between SV-40 Tag and non-transgenic rats with the
concentrations being two fold less in the SV-40 Tag rats (P
< 0.05).
Cell Proliferation and Apoptosis
Cell proliferation and apoptosis were investigated at dif-
ferent ages to gain insight into critical stages of prostate
cancer development. Trend analysis demonstrated that
starting at 2 weeks postpartum, cell proliferative indices
were significantly higher in the VP and DLP of SV-40 Tag
rats than in non-transgenic rats (P < 0.05) (Figure 4). At
Estrogen concentrations in the blood serum of SV-40 Tag  and non-transgenic rats fed AIN-76A diet Figure 2
Estrogen concentrations in the blood serum of SV-40 
Tag and non-transgenic rats fed AIN-76A diet. Each 
age group had at least 5 animals per group. Values are pre-
sented as the mean ± SEM.
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Insulin-like Growth Factor-1 concentrations in the blood  serum of SV-40 Tag and non-transgenic rats fed AIN-76A  diet Figure 3
Insulin-like Growth Factor-1 concentrations in the 
blood serum of SV-40 Tag and non-transgenic rats 
fed AIN-76A diet. Each age group had at least 5 animals 
per group. Values are presented as the mean ± SEM.
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Cell proliferation as determined by immunohistochemical  staining of Ki-67 in the ventral and dorsolateral prostates of  SV-40 Tag and non-transgenic rats fed AIN-76A diet Figure 4
Cell proliferation as determined by immunohisto-
chemical staining of Ki-67 in the ventral and dorsola-
teral prostates of SV-40 Tag and non-transgenic rats 
fed AIN-76A diet. Each age group had at least 3 transgenic 
and 2 non-transgenic animals per group. Values are pre-
sented as total number of proliferating epithelial cells divided 
by total number of epithelial cells × 100 ± SEM. Picture 
inserts are examples of brown staining for Ki-67 in ventral 
prostates of 32 week old rats. A) Example of rare proliferat-
ing cells (brown staining – arrow) for KI-67 in ventral pros-
tate from 12 week old non-transgenic rat. B) Numerous 
proliferating Ki-67 positive cells (brown stain) in ventral 
prostate of a SV-40 Tag rat; a prostatic duct with high grade 
intra-epithelial lesion showing marked tufting, papillary for-
mation, nuclear crowding and high nuclear cytoplasmic ratio.
0
5
10
15
20
25
30
35
40
45
50
55
60
65
0 2 4 6 8 1 01 21 41 61 82 02 22 42 62 83 03 2
Age (Weeks)
P
r
o
l
i
f
e
r
a
t
i
o
n
 
I
n
d
e
x
SV-40 Tag VP
Non-transgenic VP
SV-40 Tag DLP
Non-transgenic DLPBMC Cancer 2009, 9:30 http://www.biomedcentral.com/1471-2407/9/30
Page 7 of 11
(page number not for citation purposes)
10 weeks of age, when 100% of the rats had developed
high grade-PIN, cell proliferation was 7-fold and 13 fold
higher in the VP and DLP of SV-40 Tag rats than in those
of non-transgenic rats. Furthermore, at 12 weeks of age,
the cell proliferative indices in the VP and DLP of SV-40
Tag rats were 50 fold and 4.5 fold higher than those in
non-transgenic rats. The increase in cell proliferation in
SV-40 Tag versus non-transgenic rat prostate continued
through the time of necropsy at 30–32 weeks where the
proliferation indices were 54 and 51 fold higher in the VP
and DLP, respectively. The picture inserts in Figure 4 illus-
trate typical staining for the Ki-67 protein in the VP of 12
week old SV-40 Tag and non-transgenic rats.
At all ages investigated, apoptotic indices were higher in
VP and DLP of SV-40 rats than in non-transgenic rats. At
10 weeks of age, apoptotic index in the VP of SV-40 Tag
rats was 3.8% compared to less than 0.01% in the VP of
non-transgenic rats (Figure 5). The lowest apoptotic indi-
ces in the VP of SV-40 Tag rats were observed between 12–
14 weeks of age, the stretch of time in which 100% of ani-
mals develop prostate cancer. The picture inserts illustrate
typical staining for apoptotic cells in the VP of 12 week
old SV-40 Tag rats and non-transgenic rats. Similarly, the
lowest apoptotic indices in the DLP of SV-40 Tag rats
occurred at 14 weeks of age, at the time that prostate can-
cer developed in the DLP.
Biomarker Regulation
After observing high rate of cell proliferation coupled with
low apoptosis, specifically at 12–14 weeks of age when
compared to the proliferative and apoptotic indices at
younger and older ages in the VP of SV-40 Tag rats, we
investigated protein biomarkers. AR protein expression in
the VP, but not the DLP, of SV-40 Tag rats was significantly
increased by 85% when compared to those in non-trans-
genic rats (Table 2). In the VP and DLP of 12 week old SV-
40 Tag rats, we found that protein expression of ER-alpha
was significantly down-regulated by approximately 50%
compared to the VP and DLP of non-transgenic rats. IGF-
1 protein expressions in the VP and DLP of SV-40 Tag rats
were significantly increased when compared to non-trans-
genic rats by 10% and 46%, respectively. Moreover, IGF-
1R protein expression in the VP and DLP were signifi-
cantly up-regulated by 153% and 38% in SV-40 Tag rats
compared to non-transgenic rats. In addition, total-ERKs
1 and 2 protein expressions in the VP of SV-40 Tag rats
were significantly increased by 3-fold. Likewise, total-
ERKs 1 and 2 protein expressions in the DLP were signifi-
cantly up-regulated by 1.7-fold and 1.6-fold, respectively
when compared to those in non-transgenic rats.
Discussion
The detailed ontogeny study revealed that prostate cancer
in SV-40 Tag rats developed first and most extensively in
the VP as contrasted to the TRAMP (mouse) model where
prostate cancer is reported to originate in the DP/DLP
[20,24]. From our ontogeny study in SV-40 Tag rats, we
found that low grade PIN (Grade 2) developed as early as
two weeks in the VP and DLP. This is 2 weeks earlier than
had been previously reported [14]. High-grade PIN
(Grade 3), the precursor to prostate adenocarcinoma, was
observed as early as 4 weeks in the VP and at 5 to 6 weeks
in the DLP. The first incidence of prostate cancer (well-dif-
ferentiated lesions – Grade 4) developed at 10 and 14
weeks of age in the VP and DLP, respectively. By 12 weeks
of age 100% of SV-40 Tag rats developed prostate cancer
in the VP, whereas it was not until 14 weeks of age that
100% animals developed prostate cancer (Grade 4) in the
DLP. Hence, this detailed ontogeny study revealed that
prostate cancer occurred 3–5 weeks earlier than at 15
weeks of age as previously reported for SV-40 Tag rats [25].
In contrast, PIN and invasive adenocarcinoma developed
in TRAMP mice at 10 and 18 weeks of age, respectively
[26]. Even though SV-40 Tag rats are larger than TRAMP
mice (526 grams and 36 grams, respectively at 30 weeks),
prostate tumors are larger in TRAMP mice (7.59 ± 0.1.49
grams) when compared to prostate tumors/lesions in SV-
Apoptosis in the ventral and dorsolateral prostates of SV-40  Tag and non-transgenic rats fed control AIN-76A diet, start- ing at day one Figure 5
Apoptosis in the ventral and dorsolateral prostates of 
SV-40 Tag and non-transgenic rats fed control AIN-
76A diet, starting at day one. Each age group had at least 
3 transgenic and 2 non-transgenic animals per group. Values 
are presented as total number of apoptotic epithelial cells 
divided by total number of epithelial cells × 100 ± SEM. Pic-
ture inserts are examples of brown staining for apoptotic 
cells in ventral prostates of 32 week old A) non-transgenic 
rats and B) SV-40 Tag rats. In A: a normal prostatic duct lined 
by cuboidal-to-columnar epithelial cells that have abundant 
cytoplasm and uniform non-overlapping nuclei (green stain-
ing). There are infrequent apoptotic cells (brown staining – 
arrow). In B: numerous apoptotic bodies with solid mass of 
tumor, minimal glandular formation, nuclear crowding and 
cells with high nuclear cytoplasmic ratio.
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40 Tag rats (1.71 ± 0.37 grams). Furthermore, when one
considers prostate weights in non-transgenic mice (83 ± 9
mg) and non-transgenic rats (1.04 ± 0.20 gram) at 30
weeks, this results in prostate tumor to prostate tissue
weight increases of 91 fold in mice and 1.6 fold in rats.
The differences in prostate cancer origin, progression and
tumor size in these models illustrates the fact that despite
both being driven by the probasin/SV-40 Tag transgene,
there are stark differences in the development of prostate
cancer in these two rodent model.
Based on the ontogeny study, we chose 12 weeks of age as
time at which to kill rats for future mechanism of action
studies since these animals were transitioning from high
grade-PIN to prostate adenocarcinoma. For future chemo-
prevention studies, we suggest 30 weeks of age to sacrifice
rats since the majority of animals at this age have devel-
oped poorly differentiated tumors, but not severe morbid-
ity. Animals aged 32–40 weeks were not observed with
poorly differentiated tumors, most likely due to the fact
that several animals over the age of 30 weeks died because
of disease progression and related factors prior to their
designated sacrifice date.
Testosterone concentrations were lowest in the youngest
animals investigated (4 weeks old), peaked at 8 and 12
weeks in SV-40 Tag and non-transgenic rats, respectively,
and declined thereafter to level off at 24 to 30 weeks of
age. DHT concentrations were moderately high at 4 weeks
of age, peaked at 8 weeks in SV-40 Tag rats, and decreased
thereafter, with the lowest concentrations at 24 to 30
weeks. Comparing blood androgen levels at 8 weeks, we
found the testosterone and DHT concentrations to be 3.9-
fold and 2.3-fold higher in SV-40 Tag rats than in non-
transgenic rats. Since the androgen levels peak at 8 weeks,
it is quiet plausible that increasing high concentrations of
these androgens in the SV-40 Tag rats at time of high
grade-PIN facilitates early prostate cancer development
(well differentiated lesions). These changes may lay the
foundation and provide the optimal environment for fur-
ther prostate cancer progression.
As reviewed by Prins et al., researchers have speculated
that estrogens may play a role in prostate cancer causation
and promotion [27]. Our assay of estradiol-17β in blood
showed that at 4–12 weeks, non-transgenic rats compared
to SV-40 Tag rats had two fold more serum estradiol.
Although the estrogen to DHT ratio, but not the estrogen
to testosterone ratio, increased in non-transgenic rats and
SV-40 Tag rats as a function of age, this ratio was con-
stantly higher in non-transgenic rats compared to SV-40
Tag rats. Therefore, the estrogen to androgen ratio was not
correlated with prostate cancer development in the SV-40
Tag rats compared to non-transgenic rats. Testosterone
concentrations (free and conjugated testosterone) in the
blood serum were consistent with previously reported lev-
els in SV-40 Tag rats [28-30], whereas DHT and estradiol
concentrations in SV-40 Tag rats have yet to be published.
Moreover, testosterone and DHT concentrations, as well
as DHT to testosterone ratios in the blood serum of
Sprague Dawley non-transgenic rats, were within range of
previously reported values [31-33].
Elevated levels of blood IGF-1 have been associated with
an increased risk of advanced stage prostate cancer [7,34-
36]. Contrary to what might be expected, serum IGF-1 lev-
Table 2: Biomarker protein expressions in the prostate lobes of 12 week old non-transgenic and SV-40 Tag rats
Non-transgenic Ventral 
Prostate
SV-40 Tag Ventral Prostate Non-transgenic 
Dorsolateral Prostate
SV-40 Tag Dorsolateral 
Prostate
Androgen Receptor 100 ± 12 185 ± 22* 100 ± 7 116 ± 11
Estrogen Receptor-alpha 100 ± 6 49 ± 7* 100 ± 9 51 ± 7*
Insulin-like Growth Factor-
1
100 ± 3 110 ± 4* 100 ± 2 146 ± 6*
Insulin-like Growth Factor-
1-alpha Receptor
100 ± 3 253 ± 32* 100 ± 6 138 ± 3*
Total-Extracellular 
Regulating Kinase-1
100 ± 5 302 ± 64* 100 ± 19 174 ± 21*
Total-Extracellular 
Regulating Kinase-2
100 ± 4 298 ± 58** 100 ± 16 157 ± 16*
Protein expressions were determined by immunoblot analysis, except for IGF-1 levels that were determined by ELISA (n = 6 per group). Protein 
expressions for non-transgenic rats were set to 100 and those of transgenic rats are presented as percent of non-transgenic rats ± SEM. *P < 0.05 
and **P < 0.01 compared to non-transgenic rats by two-tailed Students t test.BMC Cancer 2009, 9:30 http://www.biomedcentral.com/1471-2407/9/30
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els were not the highest later in life during the progression
to poorly differentiated (advanced) prostate cancer in the
SV-40 Tag rats. Despite a poorly differentiated tumor fre-
quency of 66% at 30 weeks of age, serum IGF-1 concentra-
tions gradually declined after 30 weeks of age. The lowest
post-pubertal levels were noted in the oldest animals (40
weeks of age). IGF-1 levels in the blood serum of SV-40
Tag rats as they aged mimicked the pattern observed in
non-transgenic rats and humans but at higher concentra-
tions. This demonstrates that IGF-1 levels in the blood
serum may not be the optimal marker for cancer progres-
sion in this model, but simply reflects IGF-1 production
from the liver [37].
Because high levels of sex steroids and growth factors can
often lead to changes in cell turnover, we measured cell
proliferation and apoptosis. Cell proliferation in non-
transgenic rats was similar in the VP and DLP. Likewise, in
SV-40 Tag rats, cell proliferation was similar in the VP and
DLP, but cell proliferation was significantly higher in
prostates of SV-40 Tag rats (1.5- to 54-fold higher, the lat-
ter in adult animals). Specifically, proliferation was signif-
icantly higher in the VP at an earlier age (2 weeks
postpartum) than in the DLP (6 weeks). Increased cell
proliferation is consistent with high grade-PIN and even-
tually cancer lesions developing earlier in the VP than in
the DLP.
Apoptotic indices were similar in the VP and DLP of non-
transgenic rats and in the VP and DLP of SV-40 Tag rats.
However, there was a significantly higher rate of apoptosis
in prostates of SV-40 Tag rats compared to non-transgenic
rats. We speculate that the increase in apoptosis occurs as
a consequence of increased cell proliferation and DNA
damaged cells being less stable and more prone to cell
death. The onset of apoptosis followed the initial surge in
cell proliferation and concomitant with low grade PIN
development in both the VP and DLP. Most striking is the
dramatic decreases in apoptosis from 10–14 weeks in the
VP and from 12 to 18 weeks in the DLP. This mirrors the
transition from high grade-PIN to well differentiated
lesions (cancer). Hence, the increase in cell proliferation
and decrease in apoptosis correlate very well with cancer
formation in SV-40 Tag rats.
After noting changes in cell proliferation and apoptosis
between SV-40 Tag and non-transgenic rats, we investi-
gated proteins that could serve as biomarkers of action. AR
protein expression in the VP was higher in 12 week old
SV-40 Tag rats when compared to non-transgenic rats.
Coupling up-regulated AR with the fact that testosterone
and DHT concentrations were higher in SV-40 Tag rats
makes a strong case for increased cell proliferation in the
prostate and of prostate tumor development in this ani-
mal model. Also, we found ER-alpha protein expression
was decreased in both the VP and DLP of SV-40 Tag rats.
Concomitantly, we found significantly lower serum estro-
gen concentrations in SV-40 Tag rats at 4–12 weeks. These
lower serum estrogen concentrations can be interrupted
as reduced potential for estrogen action in SV-40 Tag pros-
tate and perhaps reduced anti-androgenic action.
IGF-1 levels in the VP and DLP were elevated in SV-40 Tag
rats compared to those in non-transgenic rats. Therefore,
IGF-1 in the prostate tissue appears to be an important
protein involved in prostate cancer development in this
model. In addition to the growth factor ligand IGF-1
being altered, IGF-1R and total-ERKs 1 and 2 protein
expressions were up-regulated in the VP when SV-40 Tag
rats were compared to non-transgenic rats. Taken
together, the up-regulation of the AR, IGF-1 signaling pro-
teins, and their downstream effectors (ERKs) suggest a
potential mechanism for prostate cancer development in
the SV-40 Tag rat model. Therefore, chemopreventive and
therapeutic agents with the ability to modulate these path-
ways make attractive candidates for prevention and ther-
apy in this model.
The SV-40 Tag rat and TRAMP models are similar in some
respects. As observed in humans, prostate cancer in SV-40
rats is initiated early in life [14,38]. In both models, the
SV-40 large T antigen is under control of the probasin pro-
moter allowing androgen-regulated protein expression
specific to the epithelium of the prostate. Transformation
in the prostate occurs when the SV-40 large T antigen acts
as an oncoprotein via interactions with retinoblastoma
[39] and p53 tumor suppressor gene products [40,41].
The small t antigen may also play a role in promotion by
interacting with protein phosphatases [42].
Conclusion
The SV-40 Tag rat provides an alternative transgenic
rodent model of prostate cancer. Our ontogeny study
demonstrates that transition from PIN to well differenti-
ated tumor formation occurs from 10 to 12 weeks in the
VP and at 14 weeks in the DLP of SV-40 Tag rats. The
development of prostate cancer first in the VP of SV-40
rats is to be contrasted to that in TRAMP mice where it first
develops in the DLP. An advantage of the SV-40 Tag rat
over the TRAMP model is that prostates at 12 weeks in the
former are 25 times as large (781 ± 50 mg) as compared
in the latter (31 ± 2 mg), allowing for a greater number of
mechanism of action experiments to be conducted using
fewer animals. Although the cost of housing rats is
roughly twice as expensive as mice, the ability to use fewer
animals reduces the overall cost in the long run.
The SV-40 Tag rat displays other unique characteristics
including reported complete androgen dependence, low
metastasis, and androgen-independent metastasizingBMC Cancer 2009, 9:30 http://www.biomedcentral.com/1471-2407/9/30
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taste bud neuroblastomas [43]. In fact, Asamoto et al.
reported that castration at 20 weeks of age (after prostate
tumors had developed) caused complete regression and
involution of these adenocarcinomas and earlier castra-
tion at 5 weeks of age completely inhibited prostate aden-
ocarcinomas [14]. More detailed studies are merited to
confirm this important characteristic. In contrast, cas-
trated 12 week old TRAMP mice still developed poorly dif-
ferentiated tumors with metastatic potential [15,44].
When castrated at 4 weeks of age (prior to high grade-PIN
development), some TRAMP mice developed androgen-
independent prostate cancer. Although the SV-40 Tag rat
may never replace the TRAMP model, it is an additional
model that can be tailored to specific studies. In the
TRAMP model, the ability to progress to androgen inde-
pendence [15,44,45], allows it to be used to study late
stage prostate cancer. On the other hand, because of its
reported androgen dependence [14] and the fact that
most human prostate cancer is androgen dependent
before androgen ablation treatment, the SV-40 Tag rat
model could be useful in studying early stage prostate can-
cer. The models compliment each other. It is currently
unknown which lobe in the rat prostate is homologous to
the peripheral zone, where prostate cancer occurs in the
humans. Therefore, both the DLP and VP should be inves-
tigated. Since prostate cancer develops first and to the
greatest degree in the DP/DLP of the TRAMP model, it is
an ideal model to study prostate cancer in that portion of
the prostate. On the other hand, prostate cancer develops
first and most extensively in the VP prostate of SV-40 Tag
rats, thus providing a basis to study prostate cancer in the
VP with this model.
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